Movatterモバイル変換


[0]ホーム

URL:


NO20060877L - Dianyl and aryl heteroarlurea derivatives as modulators of 5-HT 2A serotonin receptors useful for the prophylaxis and treatment of disorders associated with this - Google Patents

Dianyl and aryl heteroarlurea derivatives as modulators of 5-HT 2A serotonin receptors useful for the prophylaxis and treatment of disorders associated with this

Info

Publication number
NO20060877L
NO20060877LNO20060877ANO20060877ANO20060877LNO 20060877 LNO20060877 LNO 20060877LNO 20060877 ANO20060877 ANO 20060877ANO 20060877 ANO20060877 ANO 20060877ANO 20060877 LNO20060877 LNO 20060877L
Authority
NO
Norway
Prior art keywords
disorders
prophylaxis
psychosis
treatment
schizophrenia
Prior art date
Application number
NO20060877A
Other languages
Norwegian (no)
Inventor
Bradley Teegarden
Honnappa Jayakumar
Hongmei Li
Sonja Strah-Pleynet
Peter I Dosa
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm IncfiledCriticalArena Pharm Inc
Publication of NO20060877LpublicationCriticalpatent/NO20060877L/en

Links

Classifications

Landscapes

Abstract

Translated fromNorwegian

Foreliggende oppfirmelse angår spesielle pyrazolderivater med formel (I), og farmasøytiske sammensetninger derav som modulerer 5-HT2A- serotonin reseptoraktiviteten. Forbindelser og farmasøytiske sammensetninger derav er rettet mot fremgangsmåter som er nyttige i profylakse eller behandling av blodplateaggregering, hjertekarsykdom, hjerteinfarkt, forbigående iskemisk attakk, angina, slag, atrial fibrillering, reduksjon av risiko for blodproppdannelse, astma eller symptomer derav, agitasjon eller et symptom, atferdsforstyrrelser, medikamentindusert psykose, utagerende psykose. Grilles de la Tourettes syndrom, manisk forstyrrelse, organisk eller NOS-psykose, psykotisk forstyrrelse, psykose, akutt schizofreni, kronisk schizofreni, NOS schizofreni og henhørende forstyrrelser, søvnforstyrrelser, diabetesrelaterte forstyrrelser, og liknende. Foreliggende oppfirmelse angår også fremgangsmåter av profylakse eller behandling av 5-HT2A serotonin formidlete forstyrrelser i kombinasjon med en dopamin-D2-reseptorantagonist, slik som et haloperidol, tilført separat eller samtidig.The present invention relates to particular pyrazole derivatives of formula (I), and to pharmaceutical compositions thereof which modulate the 5-HT 2A serotonin receptor activity. Compounds and pharmaceutical compositions thereof are directed to methods useful in prophylaxis or treatment of platelet aggregation, cardiovascular disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reduction of risk of blood clotting, asthma or symptoms, agitation or symptoms, behavioral disorders, drug-induced psychosis, debilitating psychosis. Grilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and associated disorders, sleep disorders, diabetes-related disorders, and the like. The present invention also relates to methods of prophylaxis or treatment of 5-HT 2A serotonin mediated disorders in combination with a dopamine-D 2 receptor antagonist, such as a haloperidol, administered separately or simultaneously.

NO20060877A2003-07-222006-02-22 Dianyl and aryl heteroarlurea derivatives as modulators of 5-HT 2A serotonin receptors useful for the prophylaxis and treatment of disorders associated with thisNO20060877L (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US48957203P2003-07-222003-07-22
US50358603P2003-09-162003-09-16
PCT/US2004/023488WO2005012254A1 (en)2003-07-222004-07-21Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto

Publications (1)

Publication NumberPublication Date
NO20060877Ltrue NO20060877L (en)2006-02-22

Family

ID=34118806

Family Applications (1)

Application NumberTitlePriority DateFiling Date
NO20060877ANO20060877L (en)2003-07-222006-02-22 Dianyl and aryl heteroarlurea derivatives as modulators of 5-HT 2A serotonin receptors useful for the prophylaxis and treatment of disorders associated with this

Country Status (29)

CountryLink
US (9)US8754238B2 (en)
EP (1)EP1558582B1 (en)
JP (3)JP4198733B2 (en)
KR (1)KR101157272B1 (en)
CN (3)CN101875961B (en)
AR (1)AR045069A1 (en)
AT (1)ATE313532T1 (en)
AU (1)AU2004261582C1 (en)
BR (1)BRPI0412263B1 (en)
CA (1)CA2533369C (en)
DE (1)DE602004000260T2 (en)
DK (1)DK1558582T3 (en)
EA (1)EA009732B1 (en)
EC (1)ECSP066269A (en)
ES (1)ES2258760T3 (en)
HR (1)HRP20060100T3 (en)
IL (1)IL172582A0 (en)
IS (1)IS2232B (en)
MA (1)MA28066A1 (en)
MX (1)MXPA06000795A (en)
MY (1)MY141862A (en)
NO (1)NO20060877L (en)
NZ (1)NZ544331A (en)
PL (1)PL1558582T3 (en)
PT (1)PT1558582E (en)
RS (1)RS20060035A (en)
TN (1)TNSN06017A1 (en)
TW (1)TW200523253A (en)
WO (1)WO2005012254A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2005012254A1 (en)2003-07-222005-02-10Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
CN1926114B (en)2004-03-232011-08-24艾尼纳制药公司 Process for the preparation of substituted N-aryl-N'-'3-(1H-pyrazol-5-yl)phenylureas and intermediates thereof
PE20061130A1 (en)*2004-11-192007-01-05Arena Pharm Inc 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR
US20080015223A1 (en)*2004-12-032008-01-17Arena Pharmaceuticals, Inc.Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
WO2006078610A1 (en)*2005-01-192006-07-27Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
AR052886A1 (en)*2005-01-262007-04-11Arena Pharm Inc PROCEDURES TO PREPARE PHENYLPIRAZOL REPLACED UREAS AND TO OBTAIN YOUR SYNTHESIS INTERMEDIARIES
WO2006089871A2 (en)*2005-02-232006-08-31Neurosearch A/SDiphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
JP4559262B2 (en)2005-03-072010-10-06学校法人関西医科大学 Determination method of arteriosclerosis and diabetic nephropathy
WO2007041409A1 (en)*2005-09-292007-04-12Arena Pharmaceuticals, Inc.Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
JP2009537556A (en)*2006-05-182009-10-29アリーナ ファーマシューティカルズ, インコーポレイテッド Acetamide derivatives as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors
EP3395816A1 (en)*2006-05-182018-10-31Arena Pharmaceuticals, Inc.Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
NZ594353A (en)2006-05-182013-02-22Arena Pharm IncCrystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
JP5406018B2 (en)2006-05-182014-02-05アリーナ ファーマシューティカルズ, インコーポレイテッド Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof
WO2008027483A1 (en)*2006-08-312008-03-06Arena Pharmaceuticals, Inc.Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (en)2006-10-032013-11-21Arena Pharm IncPyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CA2693369A1 (en)*2007-07-172009-01-22Allergan, Inc.Methods for treating anxiety
ES2421237T7 (en)2007-08-152013-09-30Arena Pharmaceuticals, Inc. Imidazo [1,2-a] pyridine derivatives as modulators of the serotonergic 5ht2a receptor in the treatment of disorders related thereto
EP2222301B1 (en)2007-12-132014-10-08Vanda Pharmaceuticals Inc.Method and composition for treating an alpha adrenoceptor-mediated condition
SI2222300T1 (en)2007-12-132014-11-28Vanda Pharmaceuticals Inc.Method and composition for treating a serotonin receptor-mediated condition
WO2009123714A2 (en)2008-04-022009-10-08Arena Pharmaceuticals, Inc.Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
FR2930552B1 (en)*2008-04-242012-10-12Centre Nat Rech Scient N-ACYLTHIOUREES AND N-ACYLUREES INHIBITORS OF THE HEDGEHOG PROTEIN SIGNALING PATHWAY
US9126946B2 (en)2008-10-282015-09-08Arena Pharmaceuticals, Inc.Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TR201805216T4 (en)*2008-10-282018-06-21Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
EP2308866A1 (en)*2009-10-092011-04-13Bayer CropScience AGPhenylpyri(mi)dinylpyrazoles and their use as fungicides
JP5692838B2 (en)*2009-12-152015-04-01公立大学法人横浜市立大学 Sensory organ model animal
US8980891B2 (en)2009-12-182015-03-17Arena Pharmaceuticals, Inc.Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
KR20130143091A (en)2010-11-222013-12-30알러간, 인코포레이티드Novel compounds as receptor modulators with therapeutic utility
US8461179B1 (en)2012-06-072013-06-11Deciphera Pharmaceuticals, LlcDihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2018516992A (en)*2015-06-122018-06-28アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prevention and treatment of REM sleep behavior disorder
CA2992518A1 (en)*2015-07-152017-01-19Axovant Sciences GmbhDiaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20190046506A1 (en)*2017-08-102019-02-14Axovant Sciences GmbhUse of 5ht2a inverse agonists for treating psychosis
US11723579B2 (en)2017-09-192023-08-15Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement
US11427556B2 (en)2017-11-172022-08-30Hepagene Therapeutics (HK) LimitedUrea derivatives as inhibitors of ASK1
US11717686B2 (en)2017-12-042023-08-08Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en)2017-12-312025-04-22NeuroLight, Inc.Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en)2017-12-312022-03-15Neuroenhancement Lab, LLCMethod and apparatus for neuroenhancement to enhance emotional response
BR112020015572A2 (en)2018-01-312021-02-02Deciphera Pharmaceuticals, Llc combination therapy for the treatment of mastocytosis
WO2019152711A1 (en)2018-01-312019-08-08Diciphera Pharmaceuticals Llc.Combination therapy for the treatment of gastrointestinal stromal tumors
US11364361B2 (en)2018-04-202022-06-21Neuroenhancement Lab, LLCSystem and method for inducing sleep by transplanting mental states
EP3849410A4 (en)2018-09-142022-11-02Neuroenhancement Lab, LLC SLEEP ENHANCEMENT SYSTEM AND METHOD
EP3870292A4 (en)2018-10-262022-11-09The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109705181A (en)*2019-01-242019-05-03南开大学 A kind of preparation method of macrolide derivatives
CN114615982A (en)2019-08-122022-06-10德西费拉制药有限责任公司Ripoctinib for treating gastrointestinal stromal tumor
TWI878335B (en)2019-08-122025-04-01美商迪賽孚爾製藥有限公司Methods of treating gastrointestinal stromal tumors
IL293866A (en)2019-12-302022-08-01Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
FI4084779T3 (en)2019-12-302024-12-16Deciphera Pharmaceuticals LlcCompositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
CN113855784B (en)*2021-09-262025-04-15深圳辰扬生物科技有限公司 Antidepressant and anti-anxiety uses of peptides and complexes
JP2024546484A (en)*2021-12-102024-12-24ジーエーティーシー ヘルス コーポレーション Methods for Treating Addiction and Neurological Disorders
US11779572B1 (en)2022-09-022023-10-10Deciphera Pharmaceuticals, LlcMethods of treating gastrointestinal stromal tumors
WO2024122617A1 (en)2022-12-082024-06-13塩野義製薬株式会社Nitrogen-containing heterocycle with serotonin receptor-binding activity and carbocyclic derivative

Family Cites Families (258)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE1643310A1 (en)*1966-12-291971-06-03Dow Chemical Co 4-alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamine and its pharmacologically acceptable salts
US4099012A (en)*1975-08-281978-07-04Ciba-Geigy Corporation2-pyrazolyl-benzophenones
DE2926517A1 (en)*1979-06-301981-01-15Beiersdorf Ag SUBSTITUTED 3-ARYL-PYRAZOLE AND 5-ARYL-ISOXAZOLE AND METHOD FOR THE PRODUCTION THEREOF
DE2928485A1 (en)*1979-07-141981-01-29Bayer Ag USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS
US4366158A (en)1979-11-301982-12-28Burroughs Wellcome Co.1-(8-Quinolyl)-2-pyrrolidone and its pharmaceutical compositions
IL61721A (en)1980-12-161984-03-30Blank IzhakNitroglycerin preparations
US4555399A (en)1983-11-181985-11-26Key Pharmaceuticals, Inc.Aspirin tablet
MX2011001044A (en)1987-10-032011-03-21Lundbeck & Co As HOral formulation.
US4985352A (en)*1988-02-291991-01-15The Trustees Of Columbia University In The City Of New YorkDNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
IT1227626B (en)1988-11-281991-04-23Vectorpharma Int SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION
JPH02262627A (en)1988-12-081990-10-25Japan Synthetic Rubber Co LtdOrganic nonlinear optical element
EP0412798A3 (en)1989-08-081992-07-01Merck Sharp & Dohme Ltd.Substituted pyridines, their preparation, formulations and use in dementia
US5661024A (en)*1989-10-311997-08-26Synaptic Pharmaceutical CorporationDNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5077409A (en)*1990-05-041991-12-31American Cyanamid CompanyMethod of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en)*1990-05-041992-07-07American Cyanamid CompanyBis-aryl amide and urea antagonists of platelet activating factor
FR2682379B1 (en)*1991-10-091994-02-11Rhone Poulenc Agrochimie NEW FUNGICIDAL PHENYLPYRAZOLES.
FR2690440B1 (en)*1992-04-271995-05-19Rhone Poulenc Agrochimie Arylpyrazoles fungicides.
JP3318365B2 (en)*1992-10-202002-08-26富士通株式会社 Constant voltage circuit
GB9300147D0 (en)1993-01-061993-03-03Minnesota Mining & MfgPhotothermographic materials
GB9311790D0 (en)1993-06-081993-07-28Minnesota Mining & MfgPhotothermographic materials
US5905080A (en)*1993-08-201999-05-18Smithkline Beecham, P.L.C.Amide and urea derivatives as 5HT1D receptor antagonists
US5596001A (en)1993-10-251997-01-21Pfizer Inc.4-aryl-3-(heteroarylureido)quinoline derivatves
DK122693D0 (en)1993-10-291993-10-29Hempels Skibsfarve Fab J C MARIN STRUCTURE
FR2722369B1 (en)1994-07-131998-07-10Rhone Poulenc Agrochimie FUNGICIDAL COMPOSITIONS BASED ON 3-PHENYL-PYRAZOLES FOR THE TREATMENT OF PLANT MULTIPLICATION MATERIALS, NEW 3-PHENYL-PYRAZOLES DERIVATIVES AND THEIR FUNGICIDAL APPLICATIONS
WO1996010559A1 (en)1994-10-041996-04-11Fujisawa Pharmaceutical Co., Ltd.Urea derivatives and their use as acat-inhibitors
CA2135253A1 (en)1994-11-071996-05-08Michael DennisCompound screening based on a window of chemical-messenger-independent activity
US6540981B2 (en)1997-12-042003-04-01Amersham Health AsLight imaging contrast agents
TR199700749T1 (en)1995-02-021998-02-21Smithkline Beecham P.L.C. Indole derivatives as 5-HT receptor antagonists.
US5576338A (en)1995-02-151996-11-19Merck Frosst Canada, Inc.Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
JPH11503110A (en)*1995-02-171999-03-23スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
US5856326A (en)1995-03-291999-01-05Merck & Co., Inc.Inhibitors of farnesyl-protein transferase
DE69609501T2 (en)1995-04-202001-03-29Eurand International S.P.A., Mailand/Milano COMPOSITION WITH SODIUM STARCH GLYCOLATE AS A BASIC MATERIAL AND PRODUCTS PRODUCED FROM IT
US5861431A (en)1995-06-071999-01-19Iotek, Inc.Incontinence treatment
WO1997003967A1 (en)1995-07-221997-02-06Rhone-Poulenc Rorer LimitedSubstituted aromatic compounds and their pharmaceutical use
US6054472A (en)*1996-04-232000-04-25Vertex Pharmaceuticals, IncorporatedInhibitors of IMPDH enzyme
US6005008A (en)*1996-02-161999-12-21Smithkline Beecham CorporationIL-8 receptor antagonists
AUPN842196A0 (en)1996-03-051996-03-28Fujisawa Pharmaceutical Co., Ltd.New compound
GB9607219D0 (en)*1996-04-041996-06-12Smithkline Beecham PlcNovel compounds
AU735545B2 (en)*1996-05-242001-07-12Neurosearch A/SPhenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
EP0910358A1 (en)1996-05-241999-04-28Neurosearch A/SPhenyl derivatives useful as blockers of chloride channels
IL127667A0 (en)*1996-06-271999-10-28Smithkline Beecham CorpIL-8 receptor antagonists
US6204285B1 (en)1996-07-012001-03-20Sepracor Inc.Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
FR2750988B1 (en)1996-07-111998-09-18Adir NOVEL 2- (1H) -QUINOLEINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE69735002T2 (en)1996-10-252006-10-26Shire Laboratories, Inc. Osmotic delivery system for soluble doses
WO1998024785A1 (en)1996-12-021998-06-11Fujisawa Pharmaceutical Co., Ltd.Indole-urea derivatives with 5-ht antagonist properties
US20010051719A1 (en)1996-12-192001-12-13Smithkline Beecham P.L.C.Novel compounds
DZ2376A1 (en)1996-12-192002-12-28Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
DE59803962D1 (en)1997-03-252002-06-06Ciba Sc Holding Ag Polycyclic compounds
US6420541B1 (en)*1998-04-142002-07-16Arena Pharmaceuticals, Inc.Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6541209B1 (en)1997-04-142003-04-01Arena Pharmaceuticals, Inc.Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
JP2002501492A (en)1997-04-222002-01-15ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Quino- and quinazolines as CRF antagonists
US6696475B2 (en)*1997-04-222004-02-24Neurosearch A/SSubstituted phenyl derivatives, their preparation and use
EP0977741B1 (en)*1997-04-222003-09-03Neurosearch A/SSubstituted phenyl derivatives, their preparation and use
EA002600B1 (en)1997-05-282002-06-27Авентис Фармасьютикалз Продактс Инк.QUINOLINE AND QUINPXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56<lck>
CA2293418A1 (en)1997-06-191998-12-23Michael Z. HoemannQuinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en)1997-06-192002-04-23Sepracor Inc.Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6207679B1 (en)1997-06-192001-03-27Sepracor, Inc.Antimicrobial agents uses and compositions related thereto
US6103905A (en)1997-06-192000-08-15Sepracor, Inc.Quinoline-indole antimicrobial agents, uses and compositions related thereto
HUP0003073A3 (en)1997-07-112002-10-28Smithkline Beecham PlcBenzenesulfonamide derivatives, process for producing them and their use as medicines
US6028083A (en)1997-07-252000-02-22Hoechst Marion Roussel, Inc.Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
WO1999006354A1 (en)1997-07-291999-02-11Smithkline Beecham CorporationIl-8 receptor antagonists
EP1007049A1 (en)1997-08-272000-06-14Hexal AGNew pharmaceutical compositions of meloxicam with improved solubility and bioavailability
JP4555468B2 (en)*1997-10-312010-09-29アベンテイス・フアルマ・リミテツド Substituted anilide
JPH11183942A (en)1997-12-191999-07-09Nippon Mitsubishi Oil Corp Electrochromic device
TR200002616T2 (en)1997-12-222000-11-21Bayer Corporation Inhibition of raf kinase using symmetric and asymmetrically substituted diphenyl ureas
DK1042305T3 (en)1997-12-222005-09-19Bayer Pharmaceuticals Corp Inhibition of p38 kinase using symmetric and asymmetric diphenylureas
US7517880B2 (en)*1997-12-222009-04-14Bayer Pharmaceuticals CorporationInhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
GB9801392D0 (en)1998-01-221998-03-18Smithkline Beecham PlcNovel compounds
GB9803411D0 (en)1998-02-181998-04-15Smithkline Beecham PlcNovel compounds
US6100291A (en)1998-03-162000-08-08Allelix Biopharmaceuticals Inc.Pyrrolidine-indole compounds having 5-HT6 affinity
WO1999052927A1 (en)*1998-04-141999-10-21Arena Pharmaceuticals, Inc.Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6251893B1 (en)1998-06-152001-06-26Nps Allelix Corp.Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US6140509A (en)*1998-06-262000-10-31Arena Pharmaceuticals, Inc.Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en)*1998-07-241998-09-23Merck Sharp & DohmeTherapeutic agents
GB9818916D0 (en)1998-08-281998-10-21Smithkline Beecham PlcUse
GB9819382D0 (en)1998-09-041998-10-28Cerebrus LtdChemical compounds I
GB9819384D0 (en)1998-09-041998-10-28Cerebrus LtdChemical compounds II
GB9820113D0 (en)1998-09-151998-11-11Merck Sharp & DohmeTherapeutic agents
US6358698B1 (en)*1998-10-072002-03-19Acadia Pharmacueticals Inc.Methods of identifying inverse agonists of the serotonin 2A receptor
EP1514867A3 (en)*1998-10-222005-03-23NeuroSearch A/SSubstituted phenyl derivatives, their preparation and use
US6403808B1 (en)1999-12-102002-06-11Virginia Commonwealth UniversitySelective 5-HT6 receptor ligands
US6150393A (en)*1998-12-182000-11-21Arena Pharmaceuticals, Inc.Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1147094A1 (en)1999-01-152001-10-24Novo Nordisk A/SNon-peptide glp-1 agonists
US6180138B1 (en)1999-01-292001-01-30Abbott LaboratoriesProcess for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
KR20020015308A (en)1999-03-262002-02-27추후보정Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
AU4038600A (en)1999-03-292000-10-16Neurogen Corporation4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
ES2291024T4 (en)1999-04-212009-03-01Nps Allelix Corp. PIPERIDINE-INDOL COMPOUNDS WITH AFFINITY WITH 5-HT6.
GB9909409D0 (en)1999-04-241999-06-23Zeneca LtdChemical compounds
US6469006B1 (en)1999-06-152002-10-22Bristol-Myers Squibb CompanyAntiviral indoleoxoacetyl piperazine derivatives
IT1312115B1 (en)1999-06-242002-04-04Nicox Sa AMORPHOUS COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS
HK1054227A1 (en)1999-07-282003-11-21阿温蒂斯药物制品公司Substituted oxoazaheterocyclyl compounds
US6541477B2 (en)1999-08-272003-04-01Scios, Inc.Inhibitors of p38-a kinase
US6566372B1 (en)1999-08-272003-05-20Ligand Pharmaceuticals IncorporatedBicyclic androgen and progesterone receptor modulator compounds and methods
MY125942A (en)1999-09-072006-09-29Upjohn CoAminoalkoxy carbazoles for the treatment of cns diseases
WO2001021160A2 (en)1999-09-232001-03-29Axxima Pharmaceuticals AktiengesellschaftCarboxymide and aniline derivatives as selective inhibitors of pathogens
GB9926302D0 (en)1999-11-052000-01-12Smithkline Beecham PlcNovel compounds
AU1542201A (en)1999-11-052001-05-14Nps Allelix Corp.Compounds having 5-HT6 receptor antagonist activity
US6531291B1 (en)*1999-11-102003-03-11The Trustees Of Columbia University In The City Of New YorkAntimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
UA75055C2 (en)1999-11-302006-03-15Пфайзер Продактс Інк.Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
EP1108720A1 (en)1999-12-082001-06-20Basf AktiengesellschaftHerbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines
JP2003516967A (en)1999-12-162003-05-20バイオストリーム セラピューティクス 1,3,4-Substituted Piperidine Analogs and Their Use in the Treatment of Addiction
CA2397681C (en)1999-12-202011-03-15Neuromed Technologies, Inc.Partially saturated calcium channel blockers
AU2001241927A1 (en)2000-02-282001-09-12Scios Inc.Inhibitors of p38-alpha kinase
JP2001244773A (en)2000-02-292001-09-07Miyota Kk Resin case for surface mount type piezoelectric vibrator, surface mount type piezoelectric vibrator, and manufacturing method thereof
US6310212B1 (en)2000-03-282001-10-30Neurogen Corporation4-substituted quinoline derivatives
PE20020063A1 (en)2000-06-202002-01-30Upjohn Co BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR
FR2810979B1 (en)*2000-06-292002-08-23Adir NOVEL DIPHENYLUREA DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SE0002754D0 (en)2000-07-212000-07-21Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
GB0021450D0 (en)2000-08-312000-10-18Smithkline Beecham PlcNovel compounds
GB0021885D0 (en)2000-09-062000-10-18Fujisawa Pharmaceutical CoNew use
US6576644B2 (en)2000-09-062003-06-10Bristol-Myers Squibb Co.Quinoline inhibitors of cGMP phosphodiesterase
CZ20031145A3 (en)2000-10-022003-12-17Janssen Pharmaceutica N.V.Antagonists of metabotropic glutamate receptor
EP1326830A1 (en)2000-10-202003-07-16Biovitrum Ab2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10053813A1 (en)2000-10-302002-05-08Bayer Ag New use of sulfonamides
EA006205B1 (en)2000-11-022005-10-27Уайт1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002039987A2 (en)2000-11-142002-05-23Neurosearch A/SUse of malaria parasite anion channel blockers for treating malaria
JP2004517826A (en)2000-11-212004-06-17スミスクライン ビーチャム パブリック リミテッド カンパニー Isoquinoline derivatives useful in treating CNS disorders
ATE337780T1 (en)2000-11-242006-09-15Smithkline Beecham Plc INDOLY LSULPHONYL COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
ES2188344B1 (en)2000-11-292004-09-16Laboratorios Vita, S.A. COMPOUNDS DERIVED FROM BENZOTIOPHENE, ITS PROCEDURE FOR OBTAINING AND USING THEMSELVES.
AR035521A1 (en)2000-12-222004-06-02Lundbeck & Co As H DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM
JP2004520347A (en)2001-01-152004-07-08グラクソ グループ リミテッド Arylpiperidine and piperazine derivatives as inducers of LDL-receptor expression
WO2002076464A1 (en)*2001-03-222002-10-03Arena Pharmaceuticals, Inc.Anti-psychosis combination
US7157488B2 (en)2001-03-292007-01-02Eli Lilly And CompanyN-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor
GB0111186D0 (en)2001-05-082001-06-27Smithkline Beecham PlcNovel compounds
ATE353318T1 (en)2001-06-072007-02-15Hoffmann La Roche NEW INDOLE DERIVATIVES WITH AFFINITY TO THE 5-HT6 RECEPTOR
JP2005501019A (en)2001-06-152005-01-13エフ.ホフマン−ラ ロシュ アーゲー 4-piperazinylindole derivatives having 5-HT6 receptor affinity
ITRM20010356A1 (en)2001-06-212002-12-23Sigma Tau Ind Farmaceuti "5-HALOGEN TRIPTAMIN DERIVATIVES USEFUL AS LIGANDS OF THE 5-HT6 AND / OR 5-HT7 SEROTONIN RECEPTOR.
ES2295379T3 (en)2001-06-292008-04-16Eurand Pharmaceuticals Ltd. PROCEDURE FOR THERMODYNAMIC ACTIVATION OF INSOLUBLE MEDICINES IN WATER LOADED IN RETICULATED POLYMERS.
CA2452743A1 (en)2001-08-032003-02-13Pharmacia & Upjohn Company5-arylsulfonyl indoles having 5-ht6 receptor affinity
WO2003013510A1 (en)2001-08-072003-02-20Smithkline Beecham P.L.C.3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP4187650B2 (en)2001-08-102008-11-26エフ.ホフマン−ラ ロシュ アーゲー Arylsulfonyl derivatives having 5-HT6 receptor affinity
JP4733877B2 (en)2001-08-152011-07-27富士通セミコンダクター株式会社 Semiconductor device
DK1425272T3 (en)2001-08-312011-11-21Novartis Ag Optical isomers of an iloperidone metabolite
EP1427415B1 (en)*2001-09-212009-08-12Brystol-Myers Squibb CompanyLactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003035061A1 (en)2001-10-232003-05-01Biovitrum AbUse of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
SE0103649D0 (en)2001-11-012001-11-01Astrazeneca Ab Therapeutic quinoline compounds
EP1456178A1 (en)2001-12-212004-09-15Smithkline Beecham Plc7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
EP1509505A2 (en)*2002-01-232005-03-02Arena Pharmaceuticals, Inc.SMALL MOLECULE MODULATORS OF THE 5&minus;HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
EP1471912A1 (en)2002-02-052004-11-03Glaxo Group LimitedMethod of promoting neuronal growth
GB0202679D0 (en)2002-02-052002-03-20Glaxo Group LtdNovel compounds
ES2260607T3 (en)2002-02-132006-11-01Glaxo Group Limited DERIVATIVES OF 7-ARILSULFONAMIDO-2,3,4,5-TETRAHIDRO-1H-BENZO-DIAZEPINA AFFINISHED BY 5-HT6 RECEPTORS FOR THE TREATMENT OF CNS DISORDERS.
EP1478361A2 (en)2002-02-222004-11-24PHARMACIA &amp; UPJOHN COMPANYArylsulfone derivatives
US6743864B2 (en)2002-03-122004-06-01Basell Poliolefine Italia S.P.A.Polyolefin compositions having high tenacity
EP1497291B1 (en)2002-03-272006-11-22Glaxo Group LimitedQuinoline and aza-indole derivatives and their use as 5-ht6 ligands
NZ535239A (en)2002-03-272008-03-28Glaxo Group LtdQuinoline derivatives and their use as 5-HT6 ligands
PL211057B1 (en)2002-05-132012-04-30Hoffmann La RocheBenzoxazine derivatives as 5-ht6 modulators and uses thereof
WO2004034963A2 (en)2002-05-172004-04-29Eisai Co., Ltd.Methods and compositions using cholinesterase inhibitors
PL374401A1 (en)2002-06-052005-10-17F.Hoffmann-La Roche Ag1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
SG156524A1 (en)2002-06-202009-11-26Biovitrum Ab PublNew compounds useful for the treatment of obesity, type ii diabetes and cns disorders
US7943639B2 (en)2002-06-202011-05-17Proximagen LimitedCompounds
ES2287518T3 (en)2002-09-172007-12-16F. Hoffmann-La Roche Ag INDOLES 2,7-REPLACED AND ITS EMPLOYMENT AS MODULATORS OF 5-HT6.
PL376022A1 (en)2002-09-172005-12-12F.Hoffmann-La Roche Ag2,4-substituted indoles and their use as 5-ht6 modulators
WO2004028450A2 (en)2002-09-242004-04-08Arena Pharmaceuticals, Inc.Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof
US7635709B2 (en)2002-09-262009-12-22The United States Of America As Represented By The Department Of Veterans AffairsCompositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2004035047A1 (en)2002-10-182004-04-29F. Hoffmann-La Roche Ag4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
JP4401297B2 (en)2002-11-082010-01-20エフ.ホフマン−ラ ロシュ アーゲー Substituted benzoxazinone and uses thereof
TW200529597A (en)2002-11-082005-09-01Interdigital Tech CorpComposite channel quality estimation techniques for wireless receivers
JPWO2004046110A1 (en)2002-11-152006-03-16アステラス製薬株式会社 Melanin-concentrating hormone receptor antagonist
PL377464A1 (en)2002-12-032006-02-06F. Hoffmann-La Roche AgAminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
WO2004058722A1 (en)2002-12-242004-07-15Arena Pharmaceuticals, Inc.Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
EP1594512A4 (en)2003-02-112007-07-11Kemia IncCompounds for the treatment of viral infection
ATE429228T1 (en)2003-02-142009-05-15Serono Lab DERIVATIVES OF PIPERAZINE-2-CARBOXAMIDE
TW200418830A (en)2003-02-142004-10-01Wyeth CorpHeterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
PL378120A1 (en)2003-02-142006-03-06WyethHeterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
JP2006515341A (en)2003-03-032006-05-25エフ.ホフマン−ラ ロシュ アーゲー 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators
GB0305575D0 (en)2003-03-112003-04-16Glaxo Group LtdNovel compounds
TWI289141B (en)2003-03-112007-11-01Hoffmann La Roche F. Ag.Quinolinone derivatives and uses thereof
WO2004085433A2 (en)2003-03-282004-10-07Pharmacia & Upjohn Company LlcPositive allosteric modulators of the nicotinic acetylcholine receptor
GB0309781D0 (en)2003-04-292003-06-04Glaxo Group LtdCompounds
EP1695966A1 (en)2003-07-222006-08-30Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2005012254A1 (en)2003-07-222005-02-10Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related therto
EP1653960A4 (en)2003-08-132008-11-26Amgen IncMelanin concentrating hormone receptor antagonist
US7091236B1 (en)2003-08-202006-08-15Sciele Pharma, Inc.Method for increasing the bioavailability of glycopyrrolate
GB0320320D0 (en)2003-08-292003-10-01Glaxo Group LtdNovel compounds
US20050054691A1 (en)*2003-08-292005-03-10St. Jude Children's Research HospitalCarboxylesterase inhibitors
AU2004268918A1 (en)2003-09-032005-03-10Galapagos NvImidazo(1,5-a)pyridine or imidazo(1,5-a)piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders
GB0321473D0 (en)2003-09-122003-10-15Glaxo Group LtdNovel compounds
GB0322510D0 (en)2003-09-252003-10-29Glaxo Group LtdNovel compounds
PT1667975E (en)2003-09-262008-02-29Glaxo Group LtdA polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline
SE0302760D0 (en)2003-10-202003-10-20Biovitrum Ab New compounds
WO2005066157A1 (en)2004-01-022005-07-21Suven Life Sciences3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
WO2005077345A1 (en)2004-02-032005-08-25Astrazeneca AbCompounds for the treatment of gastro-esophageal reflux disease
US20070293539A1 (en)2004-03-182007-12-20Lansbury Peter TMethods for the treatment of synucleinopathies
CN1926114B (en)2004-03-232011-08-24艾尼纳制药公司 Process for the preparation of substituted N-aryl-N'-'3-(1H-pyrazol-5-yl)phenylureas and intermediates thereof
GB0407025D0 (en)2004-03-292004-04-28Glaxo Group LtdNovel compounds
GB0411421D0 (en)2004-05-212004-06-23Glaxo Group LtdNovel compounds
JP2008501758A (en)2004-06-092008-01-24グラクソ グループ リミテッド Pyrrolopyridine derivatives
WO2006004722A2 (en)*2004-06-302006-01-12Biomol Research Laboratories, Inc.Compositions and methods for selectively activating human sirtuins
TW200616608A (en)2004-07-092006-06-01Forest LaboratoriesMemantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060172992A1 (en)2004-08-132006-08-03Eisai Co., Ltd.Therapeutic agent for overactive bladder resulting from cerebral infarction
EP1786422A2 (en)2004-08-162007-05-23Prosidion LimitedAryl urea derivatives for treating obesity
US20060063754A1 (en)*2004-09-212006-03-23Edgar Dale MMethods of treating a sleep disorder
GB0422263D0 (en)2004-10-072004-11-10Glaxo Group LtdNovel compounds
CA2584485C (en)*2004-10-202013-12-31Resverlogix Corp.Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
WO2006049941A2 (en)2004-10-272006-05-11Neurogen CorporationDiaryl ureas as cb1 antagonists
WO2006049734A2 (en)2004-10-292006-05-11Hypnion, Inc.Quetiapine analogs and methods of use thereof
EP1814558B1 (en)2004-11-012010-12-15Seo Hong YooMethods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
GB0425548D0 (en)2004-11-192004-12-22Glaxo Group LtdRadiolabelled ligands
PE20061130A1 (en)*2004-11-192007-01-05Arena Pharm Inc 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR
AR051978A1 (en)2004-12-012007-02-21Divergence Inc PESTICIDED COMPOSITIONS AND METHODS
GB0426313D0 (en)2004-12-012005-01-05Merck Sharp & DohmeTherapeutic agents
US20080015223A1 (en)*2004-12-032008-01-17Arena Pharmaceuticals, Inc.Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
DE102004061593A1 (en)2004-12-212006-06-22Abbott Gmbh & Co. Kg Substituted N-heterocyclic compounds and their therapeutic use
EP1831172B1 (en)2004-12-282009-02-18Council of Scientific and Industrial ResearchSubstituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
US7625931B2 (en)2005-01-142009-12-01Cgi Pharmaceuticals, Inc.Certain substituted diphenyl ureas, as modulators of kinase activity
WO2006078610A1 (en)2005-01-192006-07-27Arena Pharmaceuticals, Inc.Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
WO2006078948A2 (en)2005-01-212006-07-27Teva Pharmaceutical Industries Ltd.Stable pharmaceutical formulations of zonisamide and methods for their manufacture
AR052886A1 (en)2005-01-262007-04-11Arena Pharm Inc PROCEDURES TO PREPARE PHENYLPIRAZOL REPLACED UREAS AND TO OBTAIN YOUR SYNTHESIS INTERMEDIARIES
EP1846415B1 (en)2005-01-272012-08-01Janssen Pharmaceutica NVHeterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
GT200600042A (en)2005-02-102006-09-27Aventis Pharma Inc BIS ARILO AND HETEROARILO COMPOUNDS REPLACED AS SELECTIVE ANTAGONISTS OF 5HT2A
WO2006089871A2 (en)2005-02-232006-08-31Neurosearch A/SDiphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
GB0504828D0 (en)2005-03-092005-04-13Merck Sharp & DohmeTherapeutic agents
GB0505437D0 (en)2005-03-172005-04-20Merck Sharp & DohmeTherapeutic agents
GB0505725D0 (en)2005-03-192005-04-27Merck Sharp & DohmeTherapeutic agents
TWI320783B (en)2005-04-142010-02-21Otsuka Pharma Co LtdHeterocyclic compound
CA2606473C (en)2005-04-262013-08-13Hypnion, Inc.Benzisoxazole piperazine compounds and methods of use thereof
EP1734039A1 (en)2005-06-132006-12-20Esbatech AGAryl urea compounds as BETA-secretase inhibitors
SG162804A1 (en)2005-06-272010-07-29Exelixis IncPyrazole based lxr modulators
US7754724B2 (en)2005-06-302010-07-13Dow Agrosciences LlcN-substituted piperazines
US8093401B2 (en)*2005-08-042012-01-10Sirtris Pharmaceuticals, Inc.Sirtuin modulating compounds
US7544685B2 (en)2005-08-172009-06-09H. Lundbeck A/S2,3-dihydroindole compounds
TWI329641B (en)2005-08-312010-09-01Otsuka Pharma Co Ltd(benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
GB0519765D0 (en)2005-09-282005-11-09Glaxo Group LtdNovel compounds
GB0519760D0 (en)2005-09-282005-11-09Glaxo Group LtdNovel compounds
GB0519758D0 (en)2005-09-282005-11-09Glaxo Group LtdNovel process
WO2007041409A1 (en)2005-09-292007-04-12Arena Pharmaceuticals, Inc.Pharmaceutical compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
PE20071143A1 (en)2006-01-132008-01-20Wyeth Corp PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST
WO2007103286A2 (en)2006-03-022007-09-13Spherics, Inc.Rate-controlled bioadhesive oral dosage formulations
EP2004627A2 (en)2006-04-102008-12-24Arena Pharmaceuticals, Inc.3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0608655D0 (en)2006-05-032006-06-14Merck Sharp & DohmeTherapeutic Treatment
JP5406018B2 (en)2006-05-182014-02-05アリーナ ファーマシューティカルズ, インコーポレイテッド Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof
NZ594353A (en)2006-05-182013-02-22Arena Pharm IncCrystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP3395816A1 (en)2006-05-182018-10-31Arena Pharmaceuticals, Inc.Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP2009537556A (en)2006-05-182009-10-29アリーナ ファーマシューティカルズ, インコーポレイテッド Acetamide derivatives as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors
WO2008027483A1 (en)2006-08-312008-03-06Arena Pharmaceuticals, Inc.Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (en)*2006-10-032013-11-21Arena Pharm IncPyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TW200823204A (en)*2006-10-172008-06-01Arena Pharm IncBiphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2008054748A2 (en)2006-10-312008-05-08Arena Pharmaceuticals, Inc.Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US9034890B2 (en)2006-11-152015-05-19Steven A. RichCombined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US8097633B2 (en)2006-11-152012-01-17Rich Steven AUses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US8969402B2 (en)2006-11-152015-03-03Steven A. RichCombined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US7998995B2 (en)2006-12-082011-08-16Exelixis Patent Company LlcLXR and FXR modulators
WO2008113818A1 (en)2007-03-212008-09-25Glaxo Group LimitedUse of quinoline derivatives in the treatment of pain and irritable bowel syndrome
ES2421237T7 (en)2007-08-152013-09-30Arena Pharmaceuticals, Inc. Imidazo [1,2-a] pyridine derivatives as modulators of the serotonergic 5ht2a receptor in the treatment of disorders related thereto
EP2254564A1 (en)2007-12-122010-12-01Glaxo Group LimitedCombinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en)2008-04-022009-10-08Arena Pharmaceuticals, Inc.Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en)2008-10-282015-09-08Arena Pharmaceuticals, Inc.Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TR201805216T4 (en)2008-10-282018-06-21Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
GB201111712D0 (en)2011-07-082011-08-24Gosforth Ct Holdings Pty LtdPharmaceutical compositions
EP3718547A1 (en)2011-10-032020-10-07The University of Utah Research FoundationApplication of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
JO3459B1 (en)2012-09-092020-07-05H Lundbeck As Pharmaceutical formulations for the treatment of Alzheimer's disease
JOP20210047A1 (en)2012-10-252017-06-16Otsuka Pharma Co LtdProphylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
WO2014085362A1 (en)2012-11-272014-06-05Acadia Pharmaceuticals Inc.Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR101472682B1 (en)2013-07-232014-12-15고려대학교 산학협력단Methode for preparing metamaterial, metamaterial film prepared by the same and super-resolution imaging system using the the same
US9478471B2 (en)2014-02-192016-10-25Taiwan Semiconductor Manufacturing Company, Ltd.Apparatus and method for verification of bonding alignment
US20160324851A1 (en)2015-05-072016-11-10Axovant Sciences, Ltd.Methods of treating a neurodegenerative disease
AU2016258198A1 (en)2015-05-072017-11-23Axovant Sciences GmbhCompositions and methods of treating a neurodegenerative disease
CA2992518A1 (en)2015-07-152017-01-19Axovant Sciences GmbhDiaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Also Published As

Publication numberPublication date
CA2533369A1 (en)2005-02-10
US20180169070A1 (en)2018-06-21
US20160374990A1 (en)2016-12-29
US20070072857A1 (en)2007-03-29
JP2008143908A (en)2008-06-26
TW200523253A (en)2005-07-16
KR101157272B1 (en)2012-06-15
EP1558582B1 (en)2005-12-21
ATE313532T1 (en)2006-01-15
EA200600295A1 (en)2006-08-25
PL1558582T3 (en)2006-05-31
US20130237541A1 (en)2013-09-12
US8871797B2 (en)2014-10-28
CN101875961A (en)2010-11-03
BRPI0412263A (en)2006-09-19
CA2533369C (en)2009-07-14
DE602004000260T2 (en)2006-08-24
MA28066A1 (en)2006-08-01
NZ544331A (en)2010-03-26
IL172582A0 (en)2006-04-10
PT1558582E (en)2006-05-31
JP2007039461A (en)2007-02-15
AU2004261582C1 (en)2010-01-07
US20230277505A1 (en)2023-09-07
DE602004000260D1 (en)2006-01-26
HRP20060100T3 (en)2007-03-31
DK1558582T3 (en)2006-05-08
ECSP066269A (en)2006-07-28
US20050080124A1 (en)2005-04-14
CN101875961B (en)2015-01-07
CN1826322B (en)2012-04-18
KR20060041260A (en)2006-05-11
ES2258760T3 (en)2006-09-01
TNSN06017A1 (en)2007-10-03
RS20060035A (en)2008-08-07
EP1558582A1 (en)2005-08-03
US8754238B2 (en)2014-06-17
US9273035B2 (en)2016-03-01
CN101871931A (en)2010-10-27
AU2004261582A1 (en)2005-02-10
HK1072943A1 (en)2005-09-16
BRPI0412263B1 (en)2019-10-15
WO2005012254A1 (en)2005-02-10
MXPA06000795A (en)2006-08-23
AR045069A1 (en)2005-10-12
MY141862A (en)2010-07-16
US9775829B2 (en)2017-10-03
EA009732B1 (en)2008-02-28
JP2006528195A (en)2006-12-14
JP4198733B2 (en)2008-12-17
IS2232B (en)2007-04-15
US20070078134A1 (en)2007-04-05
US20200397755A1 (en)2020-12-24
US20150073141A1 (en)2015-03-12
IS8241A (en)2006-01-19
CN1826322A (en)2006-08-30

Similar Documents

PublicationPublication DateTitle
NO20060877L (en) Dianyl and aryl heteroarlurea derivatives as modulators of 5-HT 2A serotonin receptors useful for the prophylaxis and treatment of disorders associated with this
NO20072986L (en) 3-Phenyl-pyrazole derivatives as modulators of 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2003062206A3 (en)Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2007120600A3 (en)3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2007136680A3 (en)3-pyraz0lyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2007136875A3 (en)Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2008054748A3 (en)Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JO2954B1 (en)Pyrazole Derivatives As Modulators Of The 5-HT2A Serotoninreceptor Useful For The Treatment Of Disorders Related Thereto
EA200800971A1 (en) PHARMACEUTICAL COMPOSITIONS OF THE MODULATOR OF 5-NTRECEPTORS OF SEROTONIN, USEFUL IN THE TREATMENT OF RELATED DISORDERS
JP2007523051A5 (en)
GT200600083A (en) OXYINDOL DERIVATIVES
TW200800186A (en)Heterocyclic compound containing nitrogen and pharmaceutical use thereof
SG176477A1 (en)Indole compounds
KR20100134667A (en) Isoquinolinone derivatives as NX3 antagonists
WO2010062323A3 (en)Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US20140228421A1 (en)Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
Kristiansen et al.Binding characteristics of the 5‐HT2A receptor antagonists altanserin and MDL 100907
ECSP055762A (en) 4-AMINO-1- (PIRIDILMETIL) PIPERIDINE REPLACED AS ANTAGONISTS OF MUSCARINIC RECEPTORS
JPWO2016199878A1 (en) Sigma receptor binding agent
Grauer et al.WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
Barrera-Hernández et al.Imide-based enones: A new scaffold that inhibits biofilm formation in Gram-negative pathogens
Schmidt et al.Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia
TH104739B (en) Pirasol derivatives are modulators of 5HT2A serotonin receptors that are useful for the treatment of disorders associated with it.
NO20092474L (en) Piperidine derivatives used to treat chemokine receptor 5 mediated diseases
TH124660A (en) 3-phenyl-pyrazole derivative It is a modifying agent of 5-HT2A serotonin receptor antagonist, which is useful for treating the symptoms associated with that substance.

Legal Events

DateCodeTitleDescription
FC2AWithdrawal, rejection or dismissal of laid open patent application

[8]ページ先頭

©2009-2025 Movatter.jp